The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Michel Sadelain

Carl June

Michel Sadelain, of Memorial Sloan Kettering Cancer Center, and Carl June, of University of Pennsylvania, are two of the recipients of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor T-cell immunotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
Clinical Roundup

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Citius Oncology announced positive topline safety and efficacy results from an investigator‑initiated phase I trial evaluating Lymphir (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account